An interventional study of Alpha Hydroxy Acids with nanocarriers and Alpha Hydroxy Acids only. in Psoriasis, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Psoriasis with a site in Egypt — 16 open to participants now, 16 under way, 2 of them phase 3. Psoriasis · Egypt.
Among the 54 studies in Psoriasis with a site in Egypt, this one is the 6th largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2024, is one of 24 with no phase, and was the 51st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →16 of the 54 studies in Psoriasis with a site in Egypt are open now. Recruiting first, the newest first:
Al-Azhar University · Sites in Egypt
Alaa Ashraf Muhammad Helal · Sites in Egypt
Ages 18+
Cairo University · Sites in Egypt
Ages 35–45 · Women only
Ahmed Ibrahim · Sites in Egypt
Ages 18+
Aswan University · Sites in Egypt
Ages 18–50 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 5 · Phase 4 9
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 40 across the 43 interventional studies, 100 across the 11 observational. Of the 27 that completed or were terminated, 2 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 54 have an industry lead sponsor. The 10 most frequent:
Al-Azhar University is the lead sponsor of 532 studies on the registry; 173 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Al-Azhar University has 3 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
3 of the studies in Psoriasis with a site in Egypt that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07892339Phase 3Cairo UniversityEfficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. | 2026-12-13 |
| NCT07352306Alaa Ashraf Muhammad HelalTopical Diacerein in Psoriasis Vulgaris | 2027-02-01 |
| NCT07713212Cairo UniversityCombined Fractional CO₂ Laser and Topical Corticosteroid Versus Topical Corticosteroid Only in the Treatment of Palmoplantar Psoriasis | 2027-02-15 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies in Psoriasis with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this double blind comparative clinical study is to evaluate the efficacy of AHAs combined with nanocarriers and their use as a non steroidal alternative drug for long term management of plaque psoriasis
Inclusion Criteria:- Mid to moderate cases according to Psoriasis Area and Severity Index (PASI).
Exclusion Criteria:
Patients received Alpha Hydroxy Acids formulated with nanocarriers.
Drug: Alpha Hydroxy Acids with nanocarriers
Patients received Alpha Hydroxy Acids only.
Drug: Alpha Hydroxy Acids only.
Patients received calcipotriol plus betamethasone.
Drug: Calcipotriol plus betamethasone
Patients received placebo comparator.
Other: Placebo.
Topical Alpha Hydroxy Acids formulated with nanocarriers applied to psoriatic plaques.
Topical Alpha Hydroxy Acids only applied to psoriatic plaques.
Drug pages: Calcipotriene · Betamethasone
Topical calcipotriol plus betamethasone ointment applied to psoriatic plaques.
Vehicle control / Placebo topical application applied to psoriatic plaques
Percentage Change in PASI Score.
Reduction in PASI score from baseline to week 8.
Time frame: Baseline and 8 weeks
Dermatology Life Quality Index (DLQI)
Changes in DLQI score to assess the impact of treatment on patients' quality of life.
Time frame: Baseline and 8 weeks).
Frequency of Adverse Events
Assessment of any adverse effects related to the applied therapies.
Time frame: Throughout the study period (up to 8 weeks)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Jul 2025, 15 months.
Of 115 non-industry interventional studies with no phase under Psoriasis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 15 months is below that.
Counting every sponsor, half of 134 studies reached it within 19 months; a quarter within 8 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.